

Original Document

IN THE UNITED STATES DISTRICT COURT
FOR THE WESTERN DISTRICT OF TEXAS
AUSTIN DIVISION

FILED

2007 JUN -1 PM 3:17

CLERK US DISTRICT COURT
WESTERN DISTRICT OF TEXAS

BY _____
DEPUTY

HAROLD WALKER and
JACQUELINE R. WALKER,

Plaintiffs,

V.

PFIZER, INC., JACQUELINE GUERRERO,
BOB DAVIS, JEANNE L. JALUFKA,
KYLE M. NELSON, JASON D. HAHN,
ROBERT G. VIAL, KATHRYN K. TRUITT,
KARI A. McLUHAN, REYNALDO
RIOJAS, FRANCISCO MEZA, JACK
BARINEAU, ERICA ZEPLIN, DEBORAH
QUINONES, W. LANCE GOODSON,
KEELY RODRIGUEZ, LEAH SILVA,
DANIEL PONCE, CELESTE ESCOBAR,
JILL GUIDRY, DANIEL TOWNSEND,
and LYNSEY ADAME,

Defendants.

CIVIL ACTION NO.

JURY REQUESTED

*Pending Transfer to MDL-1699
(In re Bextra and Celebrex Marketing,
Sales Practices and Prods. Liab. Litig.)*

DEFENDANT PFIZER INC.'S NOTICE OF REMOVAL

TO: The United States District Court for the Western District of Texas, Austin Division.

NOW COMES Defendant Pfizer Inc. (incorrectly named as “Pfizer, Inc.” and hereinafter “Pfizer”), and files this Notice of Removal of said cause to the United States District Court for the Western District of Texas, Austin Division pursuant to 28 U.S.C. §§ 1332 and 1441. In support thereof, Pfizer respectfully would show the Court as follows:

I.

Introduction

A. The Multi-District Litigation Proceedings

This is a pharmaceutical product liability case in which Plaintiffs contend they sustained injuries from Bextra®, a prescription medication co-promoted and marketed at times by Pfizer. The Judicial Panel on Multidistrict Litigation (“JPML”) has consolidated pretrial proceedings in

personal injury actions relating to Bextra® pursuant to 28 U.S.C. § 1407 and assigned the litigation to the Honorable Charles R. Breyer of the United States District Court for the Northern District of California (the “MDL Court”). *See In re Bextra & Celebrex Mktg., Sales Pracs. & Prods. Liab. Litig.*, 391 F. Supp. 2d 1377 (J.P.M.L. 2005). Because Plaintiffs allege personal injuries from Bextra®, this case will be subject to transfer to that court as a “tag-along action.” *See id.* at 1377, n.1; RULES 1.1 & 7.4(A) OF RULES FOR MULTIDISTRICT LITIGATION UNDER 28 U.S.C. § 1407, 1999 F.R.D. 425 (J.P.M.L. 2001).

B. Plaintiffs’ Lawsuit

On April 9, 2007, Plaintiffs Harold and Jacqueline Walker filed this personal injury action against Pfizer in the 421st Judicial District Court of Caldwell County, Texas, Cause No. 07-PI-168, alleging Harold Walker sustained serious and permanent injuries as a result of ingesting Bextra®. *See* PLAINTIFFS’ ORIGINAL PETITION (“PETITION”) at 1 (Exhibit 2B). Plaintiff Jacqueline Walker seeks damages for loss of consortium. *Id.* at 12. Plaintiffs contend that Pfizer, the manufacturer of Bextra®, is liable for their alleged injuries under theories of strict liability, negligence, negligent misrepresentation, fraud, and breach of warranties. *See generally id.* at 6-11.

Plaintiffs’ lawsuit also names as defendants twenty-one (21) current or former Pfizer field representatives (often called “detailers”) from around and outside the state, whom Plaintiffs allege share their Texas citizenship.¹ As Pfizer detailers, the named employees are responsible for making physicians aware of Pfizer’s products, so that the doctors can consider whether to prescribe them for particular patients. *See, e.g.,* DECLARATION OF JACQUELINE GUERRERO (“GUERRERO DECL.”) ¶ 3 (Exhibit 6A). Plaintiffs maintain that these individual employees

¹ Two of the named detailers – Kari McLuhan and Jill Guidry – are not Texas citizens, but rather are citizens of Arizona and Louisiana, respectively. *See* DECLARATION OF KARI A. MCLUHAN (“MCLUHAN DECL.”) ¶ 3 (Exhibit 6H); DECLARATION OF JILL GUIDRY (“GUIDRY DECL.”) at ¶ 3 (Exhibit 6S).

“called on doctors and hospitals” and “were in a position to make representations about the risks associated with the use of BEXTRA®,” and then obliquely suggest – with no specific supporting factual allegations – that “Defendants” failed to advise those unnamed health care providers of certain risks. See PETITION at 6; see, e.g., *Bell Atl. Corp. v. Twombly*, ___ U.S. ___, 127 S. Ct. 1955, 1964-65 & n. 3 (May 21, 2007) (holding that under Rule 8 a plaintiff must plead “more than labels and conclusions, and a formulaic recitation of the elements of a cause of action”; instead, “[f]actual allegations must be enough to raise a right to relief above the speculative level”). The gravamen of Plaintiffs’ complaint against these employees, thus, is that they failed to warn of potential adverse health effects of Bextra®. Plaintiffs also plead generally that “Defendants” are liable under product liability and breach of warranty theories.

Plaintiffs and Pfizer are of diverse citizenship. The individual Pfizer detailer employees have been improperly joined² in an effort to obstruct Pfizer’s statutory right to removal. As the Eleventh Circuit Court of Appeals recently held, it has become a “common strategy” for plaintiffs in pharmaceutical product liability cases to name local detailer defendants in an effort to defeat the diverse drug manufacturer’s right to remove a case to federal court. See *Legg v. Wyeth*, 428 F.3d 1317, 1320 (11th Cir. 2005). A federal MDL Court overseeing one such pharmaceutical product liability litigation bluntly characterized such tactics as “a sham, at the unfair expense not only of [the diverse pharmaceutical company] but of the many individuals . . . that are being unfairly dragged into court simply to prevent the adjudication of lawsuits against [the pharmaceutical company], the real target, in a federal forum.” *Anderson v. Am. Home Prods. Corp.*, 220 F. Supp. 2d 414, 425 (E.D. Pa. 2002).

² Courts historically have called this the “fraudulent joinder” doctrine. However, in *Smallwood v. Illinois Central R.R. Co.*, 385 F.3d 568, 571 n.1 (5th Cir. 2004) (en banc), the Fifth Circuit Court of Appeals adopted the term “improper joinder” as being more consistent with the related statutory language. Pfizer, consequently, uses this phraseology in this Notice.

In this case, Plaintiffs' petition sets forth no facts establishing any reasonable possibility that the individual Pfizer employees personally are liable to Plaintiffs. Indeed, the allegations in the state-court petition refer only to "Defendants" generally, without pleading any specific factual basis for a suit against the detailers. Further, even assuming the allegations could be construed as directed against the individual Pfizer employees, they are without any basis in fact. It is axiomatic that, to make a *prima facie* case against the detailers, Plaintiffs must show that those defendants have some causal connection to their alleged injuries. But there is no such connection here. *The declaration evidence establishes that two of the named employee defendants never "detailed" Bextra to any health care providers at all, and at least eighteen others never detailed the drug to Harold Walker's prescribing physician.* Further, none ever provided any information or made any statements about Bextra® to Plaintiffs, whom they do not know. These individual defendants, therefore, could not have caused or contributed to any decision to prescribe the drug to Harold Walker, and none has a causal connection to Plaintiffs' alleged injuries.³

Furthermore, and in any event, Plaintiffs fail to state any viable cause of action against the detailers as a matter of Texas substantive law. One Texas federal court after another – including this Court – has held that similar allegations against drug manufacturers' individual employees have no reasonable possibility of success under Texas law. *See, e.g., Budd v. Wyeth*, Case No. A-03-CA-465-SS, slip op. at 6 (W.D. Tex. Sept. 17, 2003) (Sparks, J.) (Exhibit 7E); *Kollman v. Wyeth*, No. A-04-CA-034-SS, slip op. at (W.D. Tex. Mar. 15, 2004) (Sparks, J.)

³ Indeed, Plaintiffs' counsel has named *the same twenty-one detailers* in at least eleven different cases filed all over the State of Texas – from Starr County in the south to Tarrant County in the north – despite the fact that some of the detailers never detailed Bextra at all and others never detailed the product in certain geographic areas, such as Caldwell County. *See generally* discussion, Part III.D., *infra*. The fact that Plaintiffs' counsel in these cases have indiscriminately thrown the same Pfizer detailers into their lawsuits despite lacking any factual connection to their alleged injuries reflects their scattershot approach to attempting to defeat federal jurisdiction.

(Exhibit 7J). The improper joinder of the individual Pfizer employees in this case likewise does not defeat diversity jurisdiction.

In sum, this action is one in which this Court has original subject matter jurisdiction under the provisions of 28 U.S.C. § 1332, and is one which may be removed to this Court by Pfizer pursuant to the provisions of 28 U.S.C. § 1441(a), in that, excluding the improperly joined defendants, it is a civil action between citizens of different states, and the matter in controversy exceeds the sum or value of \$75,000, exclusive of interest and costs. Copies of all process, pleadings, and orders filed in state court are attached hereto.

II.

Diversity of Citizenship

Plaintiffs Harold and Jacqueline Walker are, and were at the time this suit was filed, residents of Caldwell County and citizens of the State of Texas, *see* PETITION at 2, and, thus, they are Texas citizens for purposes of determining federal diversity jurisdiction.

Defendant Pfizer Inc. was at the time this suit was filed, and is presently, a corporation organized under Delaware law with its principal place of business in New York. *See* PETITION at 2. It therefore is considered a citizen of both Delaware and New York for jurisdictional purposes. *See* 28 U.S.C. § 1332(c)(1).

Defendant employee Kari A. McLuhan is, and was at the time this suit was filed, a resident and citizen of the State of Arizona. *See* MCLUHAN DECL. at ¶ 3 (Exhibit 6H).

Defendant employee Jill Guidry is, and was at the time this suit was filed, a resident and citizen of the State of Louisiana.⁴ *See* GUIDRY DECL. at ¶ 3 (Exhibit 6S).

Defendant employees Jacqueline Guerrero, Bob Davis, Jeanne L. Jalufka, Kyle M. Nelson, Jason D. Hahn, Robert G. Vial, Kathryn K. Truitt, Reynaldo Riojas, Francisco Meza,

⁴ In any event, Defendants McLuhan and Guidry are improperly joined and/or nominal parties for the same reasons discussed below with respect to the other detailers.

Jack Barineau, Erica Zeplin, Deborah Quinones, W. Lance Goodson, Keely Rodriguez, Leah Silva, Daniel Ponce, Celeste Escobar, Daniel Townsend, and Lynsey Adame (collectively referred to as the “detailers”) were at the time this suit was filed, and are presently, residents and citizens of the State of Texas. *See* PETITION at 2-4 (Exhibit 2B). However, they are improperly joined in an attempt to prevent removal, and therefore, their citizenship may be disregarded for purposes of determining diversity jurisdiction. A non-diverse defendant is deemed to be improperly joined when there is no reasonable basis to predict that the plaintiff could establish a cause of action against that party in state court. *See Smallwood v. Illinois Cent. R.R. Co.*, 385 F.3d 568, 573 (5th Cir. 2004) (en banc). As discussed below, there is no reasonable basis to predict that Plaintiffs could establish a claim against the in-state employee detailers named as defendants in this case.

III.

The Detailer Defendants Are Improperly Joined

A. The improper joinder standard.

The improper joinder doctrine prevents plaintiffs from defeating diversity jurisdiction simply by naming a defendant who shares a Plaintiffs’ state citizenship. 28 U.S.C. § 1441(b) (providing for removal jurisdiction in diversity cases “if none of the parties in interest *properly* joined and served as defendants is a citizen of the State in which such action is brought”) (emphasis added); *see generally Wecker v. Nat’l Enameling & Stamping Co.*, 204 U.S. 176, 186 (1907) (“The Federal courts should not sanction devices intended to prevent a removal to a Federal court where one has that right.”); *Legg*, 428 F.3d at 1320 (recognizing “common strategy” in pharmaceutical product liability actions of naming non-diverse local defendants against whom there is no legitimate claim in an effort to defeat pharmaceutical company’s removal rights); *see also McKinney v. Bd. Of Md. Cmty. College*, 955 F.2d 924, 928 (4th Cir.

1992) (“Congress created the removal process to protect defendants. It did not extend such protection with one hand, and with the other give plaintiffs a bag of tricks to overcome it.”).

Improper joinder is established by, *inter alia*, the “inability of the plaintiff to establish a cause of action against the non-diverse party in state court.” *Smallwood v. Illinois Cent. R.R. Co.*, 385 F.3d 568, 573 (5th Cir. 2004) (en banc) (quoting *Travis v. Irby*, 326 F.3d 644, 646-47 (5th Cir. 2003)); accord *Boone v Citigroup, Inc.*, 416 F.3d 382, 388 (5th Cir. 2005). In other words, removal is appropriate and the citizenship of a non-diverse defendant is disregarded where “there is no reasonable basis for the district court to predict that the plaintiff might be able to recover against an in-state defendant.” *Smallwood*, 385 F.3d at 573. The Fifth Circuit has emphasized that “[a] ‘mere theoretical possibility of recovery under local law’ will not preclude a finding of improper joinder.” *Id.* at 573 n.9 (quoting *Badon v. RJR Nabisco, Inc.*, 236 F.3d 282, 286 n.4 (5th Cir. 2000)). There must be a “reasonable basis” for predicting that the plaintiff might establish the non-diverse defendant’s liability on the pleaded claims to warrant remand. *Griggs v. State Farm Lloyds*, 181 F.3d 694, 699 (5th Cir. 1999) (emphasis added).

Further, merely pleading a cause of action against a non-diverse defendant is insufficient to show that the plaintiff has a reasonable possibility of recovery against that party. The court is authorized to look beyond the pleadings and engage in a summary judgment-type inquiry to determine whether improper joinder exists. *Ross v. Citifinancial, Inc.*, 344 F.3d 458, 462-63 (5th Cir. 2003) (“For fraudulent joinder *vel non*, it is well established that the district court may ‘pierce the pleadings’ and consider summary judgment type evidence.”); *Badon v. RJR Nabisco Inc.*, 224 F.3d 382, 389-90 (5th Cir. 2000) (“*Badon I*”) (“[W]e have consistently recognized that diversity removal may be based on evidence outside the pleadings.”); *Burden v. General Dynamics Corp.*, 60 F.3d 213, 217 n.18 (5th Cir. 1995) (collecting cases that authorize court to look beyond pleadings); *Legg*, 428 F.3d at 1322-23 (holding that the district court committed

legal error and abused its discretion in failing to consider undisputed affidavits submitted by detailers of defendant drug manufacturer in support of the removal of a product liability action).

B. The Plaintiffs' allegations.

Whether removal to federal court is appropriate is determined "on the basis of claims in the state court complaint as it exists at the time of removal." *Cavallini v. State Farm Mut. Auto. Ins. Co.*, 44 F.3d 256, 264 (5th Cir. 1995). Aside from listing the individual employee detailers in the "Parties" section of the Petition, Plaintiffs' *sole mention* of the detailers appears in the following two sentences:

The Sales Representative Defendants called on doctors and hospitals and were in the business of profiting from the design, manufacture, marketing, distribution, and/or sales of the prescription drug BEXTRA®. The Sales Representative Defendants were in a position to make representations about the risks associated with the use of BEXTRA®.

PETITION at 6. The remainder of the Petition's allegations refer merely to "Defendants" generally, without pleading any specific factual support for a claim against any individual employee. These kinds of general allegations against "Defendants," without alleging any actionable facts specific to the detailers, do not state a claim against the in-state defendants sufficient to defeat diversity jurisdiction. *See, e.g., Griggs*, 181 F.3d at 699 (affirming decision denying remand where state-court complaint did not allege actionable facts specific to non-diverse defendant). Indeed, Plaintiffs do not specifically allege that any individual detailer ever called upon or communicated with them or with their prescribing physician. This is an essential element of their causation case – the alleged acts of the employees must have caused or contributed to the plaintiff having taken the drug. As set forth below, the employee defendants' declarations have negated that they ever communicated with Plaintiffs. Thus, if they are to establish causation, Plaintiffs must show that the detailers caused the doctor to prescribe the drug, a necessary element of causation that they do not allege. Nor do they allege that the

prescribing physician relied on any representations from the named detailers when making his or her decision to prescribe the drug. Indeed, Plaintiffs do not even *identify* the relevant health care provider.

C. Plaintiffs' conclusory allegations against the detailers, unsupported by any specific factual basis, are insufficient to state a claim against those defendants.

"[P]leadings matter when fraudulent joinder . . . issues are decided." *Great Plains Trust Co. v. Morgan Stanley Dean Witter & Co.*, 313 F.3d 305, 328 (5th Cir. 2002). Indeed, the United States Supreme Court recently emphasized that ordinary pleading rules "require[] a 'showing,' rather than a blanket assertion, of entitlement to relief. Without some factual allegation in the complaint, it is hard to see how a claimant could satisfy the requirement of providing not only 'fair notice' of the nature of the claim, but also 'grounds' on which the claim rests." *Bell Atl. Corp. v. Twombly*, ___ U.S. ___, 127 S. Ct. 1955, 1965 n.3 (May 21, 2007) (addressing FED. R. CIV. P. 8). Thus, a plaintiff must provide "more than labels and conclusions, and a formulaic recitation of the elements of a cause of action"; instead, "[f]actual allegations must be enough to raise a right to relief above the speculative level." *Id.* at 1964-65.

In keeping with these principles, "[c]onclusory allegations, wholly lacking in specific factual support" are insufficient to defeat an improper joinder removal. *Jernigan v. Ashland Oil Co.*, 989 F.2d 812, 817 (5th Cir. 1993); *see also Great Plains Trust Co.*, 313 F.3d at 313 (stating that Fifth Circuit, in undertaking an improper joinder inquiry, "will not . . . 'accept as true conclusory allegations or unwarranted deductions of fact.'" (quoting *Collins v. Morgan Stanley Dean Witter*, 224 F.3d 496, 498 (5th Cir. 2000)). "Failure to specify a factual basis for recovery against a non-diverse party constitutes a failure to state a claim and fraudulent joinder of that

party.” *Waters v. State Farm Mut. Auto. Ins. Co.*, 158 F.R.D. 107, 109 (S.D. Tex. 1994) (citing *Doe v. Cloverleaf Mall*, 829 F. Supp. 866, 870 (S.D. Miss. 1993)).⁵

Plaintiffs’ Petition does not allege *any* case-specific fact supporting a claim against the detailers. For instance, Plaintiffs do not identify *a single doctor* whom the detailers purportedly misled, much less identify *where or when* such misrepresentations took place, the specific content of the representations, or how they caused their alleged injuries. Absent specific allegations tying the detailer employees to their claims, there is no reasonable basis to predict that Plaintiffs could recover against them under Texas law. *Cf. Staples v. Merck & Co., Inc.*, 270 F. Supp. 2d 833, 840-41 (N.D. Tex. 2003) (“In general, Plaintiffs cannot assert merely speculative and conclusory allegations in order to sustain a valid negligent misrepresentation claim.”) (citation omitted); *Sohmer v. American Medical Security, Inc.*, No. 3:02-CV-1680, 2002 WL 31323763, *2-3 (N.D. Tex. Oct. 15, 2002) (concluding that speculative and conclusory allegations of negligent misrepresentation did not support a cause of action against non-diverse insurance agency and finding agency fraudulently joined).

Plaintiffs’ allegations are so devoid of specific fact, it is impossible even to tell how they are connected to the detailer defendants. For instance, as noted above, Plaintiffs do not identify the physician who allegedly prescribed the drugs. Under virtually identical circumstances, U.S.

⁵ See also *Kyger v. Veravest Investments, Inc.*, No. 4:04-CV-94-A, 2004 WL 1043111, *2 (N.D. Tex. May 6, 2004) (“Speculative and conclusory allegations do not state a cause of action without factual support. Fraudulent joinder will be found where a plaintiff has failed to plead any specific acts of negligence against the non-diverse defendant.”) (citations omitted); *Staples v. Merck & Co.*, 270 F. Supp. 2d 833, (N.D. Tex. 2003) (“[W]hen plaintiffs make general allegations and fail to support them with specific, underlying facts, they have not established a reasonable basis for the Court to predict that relief may be granted.”) (citation omitted); *Hernandez Castellanos v. Bridgestone Corp.*, 215 F. Supp. 2d 862, 864-65 (S.D. Tex. 2002) (concluding that terse, conclusory allegation of negligence against non-diverse defendant without any supporting factual allegations did not defeat removal); *Addison v. Allstate Ins. Co.*, 58 F. Supp. 2d 729, 732-33 (S.D. Miss. 1999) (concluding non-diverse defendant was fraudulently joined where plaintiff failed to allege any factual basis for claim of liability); see also FED. R. CIV. P. 9(b) (requiring averments of fraud to be pled with particularity).

Magistrate Judge Dennis Green, of the Western District of Texas, recognized that this omission warrants a finding of improper joinder:

First, as for all of Plaintiff's causes of action, she has failed to demonstrate the proper connection between Plaintiff and the detail [sales] representatives. Under Texas law, Plaintiff's complaint "must at least provide sufficient factual information that the defendant is able to prepare a defense." How can the detail [sales] representatives prepare for a defense in this case without the name of Plaintiff's physician?

U.S. Magistrate's Report and Recommendation, *Moffett v. Wyeth*, No. DR-03-CV-069, slip op. at 4 (W.D. Tex. Dec. 17, 2003) (Exhibit 6M). The Court therefore held that "[b]ecause Plaintiff has failed to give sufficient factual information so that Defendant can prepare for a defense, a finding of fraudulent joinder is warranted."⁶ *Id.* A similar conclusion also recently was reached by Judge Hilda G. Tagle in a removed case pending in the Southern District of Texas, Brownsville Division. *See Morrow v. Wyeth*, No. B-05-209, 2005 WL 2621555, at *5 (S.D. Tex. Oct. 13, 2005). Plaintiffs here likewise have failed to give sufficient information to demonstrate a connection between themselves and the detailers, warranting a finding of improper joinder.

D. The detailers are improperly joined because they have no connection to Harold Walker having taken Bextra® or Plaintiffs' alleged injuries.

The detailer defendants named in this case have no factual connection to Plaintiffs' claims. All of Plaintiffs' causes of action against them are predicated on allegations that they participated in disseminating false or misleading information regarding the safety or risk profile of Bextra® to unnamed "doctors and hospitals." *See, e.g.*, PETITION at 6. However, at least two of the named detailers never marketed, distributed, sold, or promoted Bextra®. *See* DECLARATION OF FRANCISCO MEZA ("MEZA DECL.") ¶ 4 (Exhibit 6J); DECLARATION OF JACK BARINEAU ("BARINEAU DECL.") ¶ 3 (Exhibit 6K).

⁶ The District Court in *Moffett* elected to stay the case in order to permit the MDL court to resolve the jurisdictional issues; it consequently chose not to adopt the magistrate judge's report and recommendation. The MDL Court subsequently denied the plaintiff's remand motion after transfer. *See Moffett v. Wyeth*, No. 04-20181, slip op. (E.D. Pa. Sept. 10, 2004) (PTO 3925).

Additionally, virtually all of the other named detailers never detailed Bextra® (or any other drug) to Harold Walker's prescribing physician. Although not identified by Plaintiffs, pharmacy records obtained in conjunction with a planned pre-suit deposition noticed by Plaintiff pursuant to Texas Rule of Civil Procedure 202 reflect that Harold Walker was prescribed Bextra® by a Lockhart, Texas doctor named Dr. Samson Jesudass. *See* DECLARATION OF HOLLY L. REES AND PHARMACY RECORDS (Exhibit 6V). At least eighteen of the named employees never detailed Bextra® to Dr. Jesudass (or any other health care providers in Caldwell County). *See* GUERRERO DECL. at ¶ 7 (Exhibit 6A); JALUFKA DECL. at ¶ 8 (Exhibit 6C); NELSON DECL. at ¶ 8 (Exhibit 6D); HAHN DECL. at ¶ 8 (Exhibit 6E); VIAL DECL. at ¶ 8 (Exhibit 6F); TRUITT DECL. at ¶ 8 (Exhibit 6G); MCLUHAN DECL. at ¶ 9 (Exhibit 6H); RIOJAS DECL. at ¶ 8 (Exhibit 6I); ZEPLIN DECL. at ¶ 7 (Exhibit 6L); QUINONES DECL. at ¶ 7 (Exhibit 6M); GOODSON DECL. at ¶ 7 (Exhibit 6N); RODRIGUEZ DECL. at ¶ 7 (Exhibit 6O); SILVA DECL. at ¶ 7 (Exhibit 6P); PONCE DECL. at ¶ 7 (Exhibit 6Q); ESCOBAR DECL. at ¶ 7 (Exhibit 6R); GUIDRY DECL. at ¶ 9 (Exhibit 6S); TOWNSEND DECL. at ¶ 7 (Exhibit 6T); ADAME DECL. at ¶ 7 (Exhibit 6U). Further, none of the detailers know Plaintiffs or had contact with them regarding Bextra®. *See* GUERRERO DECL. at ¶ 8 (Exhibit 6A); DAVIS DECL. at ¶ 8 (Exhibit 6B); JALUFKA DECL. at ¶ 9 (Exhibit 6C); NELSON DECL. at ¶ 9 (Exhibit 6D); HAHN DECL. at ¶ 9 (Exhibit 6E); VIAL DECL. at ¶ 9 (Exhibit 6F); TRUITT DECL. at ¶ 9 (Exhibit 6G); MCLUHAN DECL. at ¶ 10 (Exhibit 6H); RIOJAS DECL. at ¶ 9 (Exhibit 6I); ZEPLIN DECL. at ¶ 8 (Exhibit 6L); QUINONES DECL. at ¶ 8 (Exhibit 6M); GOODSON DECL. at ¶ 8 (Exhibit 6N); RODRIGUEZ DECL. at ¶ 8 (Exhibit 6O); SILVA DECL. at ¶ 8 (Exhibit 6P); PONCE DECL. at ¶ 8 (Exhibit 6Q); ESCOBAR DECL. at ¶ 8 (Exhibit 6R); GUIDRY DECL. at ¶ 10 (Exhibit 6S); TOWNSEND DECL. at ¶ 8 (Exhibit 6T); ADAME DECL. at ¶ 8 (Exhibit 6U).

Because there is no causal connection between these detailers and Plaintiffs' alleged injuries, there is no reasonable basis to predict that Plaintiffs could recover against them in state

court. Thus, they have been improperly joined in this action. *See Legg v. Wyeth*, 428 F.3d at 1322-23 (holding that the undisputed affidavits of the named detailers were sufficient to demonstrate that they were fraudulently joined) (citing *Badon I*); *see also Hawthorne Land Co. v. Occidental Chem. Corp.*, 431 F.3d 221, 225 (5th Cir. 2005) (concluding uncontradicted affidavit establishing that non-diverse employee defendants did not have connection to plaintiff's alleged injuries demonstrated improper joinder).

Other federal courts consistently have denied remand in pharmaceutical products liability cases such as this one where the plaintiffs named non-diverse detailers who had no connection to their injuries. For example, a number of Texas federal courts have held detailers improperly joined where a plaintiff was unable to demonstrate a connection between her alleged injuries and the named defendant, either because the detailer did not call on the Plaintiffs' physician or did not detail the drugs at issue. *See, e.g., Garcia v. Wyeth*, No. 03-2595, slip op. at 4 (S.D. Tex. Sept. 18, 2003) (holding detailers who did not detail diet drugs fraudulently joined where plaintiff submitted no evidence demonstrating connection to plaintiff) (Exhibit 7S); *Thibodeaux v. Wyeth*, No. 03-2532, slip op. at 4 (S.D. Tex. Sept. 13, 2003) (same) (Exhibit 7N); *Brooks v. Wyeth*, No. 03-2210, slip op. at 5 (S.D. Tex. Aug. 13, 2003) (same) (Exhibit 7O); *Northcutt v. Wyeth*, No. 03-2665, slip op. at 5 (S.D. Tex. Aug. 13, 2003) (same) (Exhibit 7G); *Coleman v. Wyeth*, No. W-03-CA-201, slip op. at 3 (W.D. Tex. Sept. 12, 2003) (holding detailer fraudulently joined where plaintiff could not show that detailer had contact with Plaintiff's physician) (Exhibit 7P); *Holder v. Wyeth*, No. W-03-CA-205, slip op. at 3 (W.D. Tex. Sept. 10, 2003) (same) (Exhibit 7Q) (same). Other federal courts, including the federal MDL courts in both the diet drug and Rezulin® products liability litigations, have reached similar conclusions. *See, e.g., In re Diet Drugs Prods. Liab. Litig.*, No. 03-20611, 2004 WL 2203712, at *2 (E.D. Pa. Sept. 28, 2004); *In re Diet Drugs Prod. Liab. Litig.*, No. 03-20546, 2004 WL 1535828, at *11 (E.D. Pa.

July 6, 2004); *Wakefield v. American Home Products Corp.*, No. 02-20164, slip op. at 11-12 (E.D. Pa. Dec. 17, 2002) (Exhibit 7R); *Dacosta v. Novartis AG*, 180 F. Supp. 2d 1178, 1182-83 (D. Or. 2001); *In re Rezulin Prods. Liab. Litig.*, 133 F. Supp. 2d 272, 281, 286-87 (S.D.N.Y. 2001). The lack of any connection between Plaintiffs' claims and Defendants Guerrero, Jalufka, Nelson, Hahn, Vial, Truitt, McLuhan, Riojas, Meza, Barineau, Zeplin, Quinones, Goodson, Rodriguez, Silva, Ponce, Escobar, Guidry, Townsend, and Adame likewise establishes they are improperly joined.

E. Plaintiffs also have not pled any ascertainable factual connection between themselves and the remaining detailer.

Plaintiffs also have not pled any factual connection between themselves and the remaining detailer, Bob Davis. Rather, they allege only that the detailers named in this case "were in a position to make representations" about Bextra® to unidentified members of the health care community without any allegation that they promoted the drug to *Plaintiff's* prescribing physician. *See* PETITION at 6. Moreover, there is no allegation that Plaintiff's physician relied on any representations by the detailers in making his prescription decision. Accordingly, there is no reasonable basis to predict any causal connection between the detailers' statements to unspecified "doctors and hospitals" about the drug and Plaintiffs' alleged injuries.

F. In any event, Plaintiffs fail to state any viable claims against the detailer defendants.

1. Any product-liability or breach of warranty-type claims cannot establish liability on behalf of the employee detailers.

Plaintiffs' claims against the detailer employees also fail as a matter of Texas substantive law. For instance, Plaintiffs allege generally that "Defendants" are liable under strict product liability and breach of warranty theories. *See* PETITION at 6-8, 10-11. Assuming *arguendo* these allegations are directed at the individual Pfizer employees, they do not state a valid claim because the detailers are not "sellers" of the product in question. Rather, the evidence

establishes they simply are employees of the product's "seller" – which is Pfizer. *In re Diet Drugs Prods. Liab. Litig.*, No. 03-20546, 2004 WL 1535828, *10 (E.D. Pa. July 6, 2004) ("While the product's 'seller' owes the consumer a duty to warn of a product's dangers, [the pharmaceutical manufacturer], and not the sales representatives, was the 'seller.'") (applying Texas law); *see also Gordon v. Pfizer Inc.*, No. CV-06-RRA-703-E, 2006 WL 2337002, at *7 (N.D. Ala. May 22, 2006) (holding that Pfizer's detailer's "affidavit constitutes affirmative proof . . . that he is not a 'seller' or 'manufacturer.' To the contrary, he is simply a 'detailer' on behalf of his employer, Pfizer" and therefore is fraudulently joined); *DaCosta v. Novartis AG*, No. CV-01-800-BR, 2002 WL 31957424, *8 (D. Or. Mar. 1, 2002) (holding pharmaceutical detailer "merely an employee" of pharmaceutical company and was not strictly liable for drugs he promoted); *McCurtis v. Dolgencorp, Inc.*, 968 F. Supp. 1158 (S.D. Miss. 1997) (holding there was no reasonable basis to predict state law would impose strict liability upon the employees of businesses who sell products to consumers; "Such employees are not 'in the business of selling products' but rather are employed by companies that are 'in the business of selling products for use or consumption.'") (quoting RESTATEMENT (SECOND) OF TORTS § 402(A) (1965)).

a. The detailer employees are not "sellers" of prescription drugs under Texas law.

Only the "seller" of a product may be held strictly liable under Texas law for injuries caused to the end-consumer. *See, e.g., Firestone Steel Prods. Co. v. Barajas*, 927 S.W.2d 608, 613 (Tex. 1996) (explaining that only those engaged in the business of designing, manufacturing or selling a product, or otherwise introducing the product into the channels of commerce, are subject to strict products liability); *Armstrong Rubber Co. v. Urquidez*, 570 S.W.2d 374, 375 (Tex. 1978) (same). Likewise, only the "seller" is liable under a breach of warranty theory. *See, e.g., Klo-Zik Co. v. General Motors Corp.*, 677 F. Supp. 499, 507–08 (E.D. Tex. 1987) ("It is apparent that S&S does not qualify as a seller with regard to the trucks and may not be held on

an implied warranty theory in that respect.”); *Arceneaux v. Lykes Bros. Steamship Co., Inc.*, 890 S.W.2d 191, 196 n. 2 (Tex. App.—Beaumont 1994, writ denied) (“With respect to liability for breach of implied warranties, the fact that the product designer was not a seller of the product is dispositive. Implied warranties are given only by the actual sellers of products, not by others who have played some other role in the distribution of the product.”) (emphasis in original), or under a 402B misrepresentation theory. See RESTATEMENT (SECOND) OF TORTS § 402B (1965); *Crocker v. Winthrop Lab.*, 514 S.W.2d 429, 431 (Tex. 1974) (adopting § 402B and explaining that section applies to misrepresentation by “seller” of chattels).

A “seller” is one who is engaged in the business of distributing or otherwise placing the product into the stream of commerce. TEX. CIV. PRAC. & REM. CODE § 82.001(3) (defining “seller”); see also *Barajas*, 927 S.W.2d at 613; *Urquidez*, 570 S.W.2d at 375. Thus, it is not enough that a party simply was a link in the chain of distribution that ultimately placed the product in the hands of a consumer. See, e.g., *Cobb v. Dallas Fort Worth Med. Center-Grand Prairie*, 48 S.W.3d 820, 826 (Tex. App.—Waco 2001, no pet.) (explaining that, for purposes of a strict liability claim, a hospital defendant was not “in the business” of selling transpedicular hardware used during surgical procedure; rather, product was connected with provision of medical services).

The evidence tendered with this removal establishes that the detailer defendants are not “sellers” of Bextra®. The detailers are *employees* of the business (Pfizer) that allegedly distributed the product in question. See, e.g., DAVIS DECL. ¶ 3 (Exhibit 6B). Their job simply was to “make the physician aware of certain of Pfizer’s products. . . .” *Id.* They never personally sold the drug to health care professionals, pharmacies, or anyone else, and did not have any involvement in the design, manufacture, or testing of Bextra®. GUERRERO DECL. at ¶ 10 (Exhibit 6A); DAVIS DECL. at ¶ 10 (Exhibit 6B); JALUFKA DECL. at ¶ 11 (Exhibit 6C); NELSON

DECL. at ¶ 11 (Exhibit 6D); HAHN DECL. at ¶ 11 (Exhibit 6E); VIAL DECL. at ¶ 11 (Exhibit 6F); TRUITT DECL. at ¶ 11 (Exhibit 6G); MCLUHAN DECL. at ¶ 12 (Exhibit 6H); RIOJAS DECL. at ¶ 11 (Exhibit 6I); MEZA DECL. at ¶ 5 (Exhibit 6J); BARINEAU DECL. at ¶ 10 (Exhibit 6K); ZEPLIN DECL. at ¶ 11 (Exhibit 6L); QUINONES DECL. at ¶ 10 (Exhibit 6M); GOODSON DECL. at ¶ 10 (Exhibit 6N); RODRIGUEZ DECL. at ¶ 10 (Exhibit 6O); SILVA DECL. at ¶ 10 (Exhibit 6P); PONCE DECL. at ¶ 10 (Exhibit 6Q); ESCOBAR DECL. at ¶ 10 (Exhibit 6R); GUIDRY DECL. at ¶ 12 (Exhibit 6S); TOWNSEND DECL. at ¶ 10 (Exhibit 6T); ADAME DECL. at ¶ 10 (Exhibit 6U). Further, it was Pfizer – their employer – that provided *all* of the information and material the individual representatives used to “detail” Pfizer’s drugs. *See, e.g.*, DAVIS DECL. at ¶ 5.

In short, the detailers are in the business of providing services to, and are agents of, their employer, which, in turn, is in the business of putting particular products into the stream of commerce. *See, e.g., Gordon*, 2006 WL 2337002, at *7 (holding that Pfizer field representatives “are not considered to be sellers or suppliers of the prescription drugs they represent” but are “simply a ‘detailer’ on behalf of [their] employer.”); *DaCosta*, 2002 WL 31957424, *8 (holding detailer was “merely an employee” of pharmaceutical company and was not strictly liable for drugs he promoted); *McCurtis*, 968 F. Supp. at 1160 (holding there was no reasonable basis to predict state law would impose strict liability upon the employees of businesses who sell products to consumers; “Such employees are not ‘in the business of selling products’ but rather are employed by companies that are ‘in the business of selling products for use or consumption.’”) (quoting RESTATEMENT (SECOND) OF TORTS § 402(A) (1965)); *see also Crocker v. Winthrop Lab.*, 514 S.W.2d 429, 430, 433 (Tex. 1974) (holding pharmaceutical company liable under 402B misrepresentation theory as “seller” of prescription drug based on representations by its employee-agent drug sales representative). Even though the detailers’ services might make

information available to facilitate commercial distribution of Pfizer's products, they are not themselves subject to individual liability as the "seller" of their employer's prescription drugs.

Texas law is clear that service providers are not "sellers" under Texas law. *See, e.g., Ames v. Ford Motor Co.*, 299 F. Supp. 2d 678, 679 (S.D. Tex. 2003); *Loyd v. ECO Resources, Inc.*, 956 S.W.2d 110, 133 (Tex. App.-Houston [14th Dist.] 1997, no writ); *Neavaux v. Park Place Hospital, Inc.*, 656 S.W.2d 923, 926 (Tex. App.-Beaumont 1983, writ ref'd n.r.e.). Nor are entities that indirectly facilitate commercial distribution of a product, such as financing companies and financing "lessors," considered "sellers" under Texas law. *See, e.g., Cole v. Elliot Equip. Corp.*, 653 F.2d 1031, 1034-35 (5th Cir. 1981); *Willowbrook Foods, Inc. v. Grinnell Corp.*, 147 S.W.3d 492, 498 (Tex. App.-San Antonio 2004, pet. denied); *Wynn v. Kensington Mortgage and Fin. Corp.*, 697 S.W.2d 47, 50 (Tex. App.-Austin 1985, no writ). These principles of Texas law have equal applicability here, where the detailers supply only services to their employer – the product's distributor – that might facilitate the product's distribution on behalf of the employer. *See Barajas*, 927 S.W.2d at 616 ("Imposition of strict liability demands more than an incidental role in the overall marketing program of the product.").

Furthermore, the detailers have no ownership of or title to the drugs they promote, and Plaintiffs do not allege otherwise. The medications for which the detailer employees provide information are the company's, and it is the company that controls distribution into the stream of commerce. *Cf. FFE Transp. Serv. v. Fulgham*, 154 S.W.3d 84, 89 (Tex. 2004) (explaining that in providing refrigerated trailer to its contractor, company conferred "*only possession of the trailer, not a right of control*," and while in possession of the trailer, contractor "acted solely as [company's] agent to accomplish its business purpose.") (emphasis added); *Loyd*, 956 S.W.2d at 130 (stating that, under Texas law, "[t]he right of control is an important factor in determining the existence of a legal duty, and it is often the deciding factor.").

The Third Restatement makes the point more directly: “Persons assisting or providing services to product distributors, while indirectly facilitating commercial distribution of products, are not subject to liability under the rules of this Restatement.” RESTATEMENT (THIRD) OF TORTS: PRODUCTS LIABILITY § 20 cmt. g (1998) (emphasis added). In particular, “[s]ales personnel” are excluded from the class of those who “sell[] or otherwise distribute[]” a product, and are not subject to strict products liability. *Id.*; see also AM. L. PROD. LIAB. 3D § 5.45 (1987) (“[T]he ‘sellers’ [for purposes of strict liability] are the businesses, not employees who act solely as agents for their principals.”). Although the Texas Supreme Court has not yet had occasion specifically to address section 20 or comment g, its rationale is consistent with Texas law, as discussed above. Moreover, as the Fifth Circuit has noted, “[t]he Texas Supreme Court has long looked to the Restatement of Torts as an influential guide in products liability law, and has recently heavily relied on the refinements in such law reflected in Restatement Third, Torts: Products Liability.” *Cimino v. Raymark Indus., Inc.*, 151 F.3d 297, 334 (5th Cir. 1998) (citing *McKisson v. Sales Affiliates, Inc.*, 416 S.W.2d 787, 788-89 (Tex. 1967); *Caterpillar Inc. v. Shears*, 911 S.W.2d 379, 381-83 (Tex. 1995); *Barajas*, 927 S.W.2d at 613, 616).⁷

For all of these reasons, Pfizer – and not any individual detailer employee – is deemed the “seller” of the drug. Because the detailers are not considered “sellers” of the prescription pharmaceutical product at issue, they are not liable to Plaintiffs under Texas product liability or breach of warranty laws. Indeed, to hold otherwise, and subject the individual employees to liability under such theories, would run contrary to the well-established notion that an agent is

⁷ Since the publication of the Third Restatement, various Texas courts, including the Texas Supreme Court, have cited various provisions of the Third Restatement as authoritative. See, e.g., *Humble Sand & Gravel, Inc. v. Gomez*, 146 S.W.3d 170, 172 n.1, 2, 3, 183 n.23, 183 n.28, 185 n.41, 189 n.47, 191 n.52 (Tex. 2004) (citing §§ 2, 2 cmt. i, j; 6 cmt. B; 2(c)); *Bostrom Seating, Inc. v. Crane Carrier Co.*, 140 S.W.3d 681, 683 (Tex. 2004) (citing § 5); *Hernandez v. Tokai Corp.*, 2 S.W.3d 251, 257 n.9 (Tex. 1999) (citing § 2(b)); *Gen. Motors Corp. v. Sanchez*, 997 S.W.2d 584, 592 n.26 (Tex. 1999) (citing § 2 cmt. f); *Hyundai Motor Co. v. Rodriguez*, 995 S.W.2d 661, 666-67 n.23 (Tex. 1999) (citing § 2 cmt. n); *Uniroyal Goodrich Tire Co. v. Martinez*, 977 S.W.2d 328, 335 (Tex. 1998) (citing § 2(b)).

not subject to liability for torts committed by the agent's principal – “there is no principle of ‘respondeat inferior.’” RESTATEMENT (THIRD) OF AGENCY § 7.01 cmt. d (2006); *see also Tri v. J.T.T.*, 162 S.W.3d 552, 562 (Tex. 2005) (explaining “individual liability arises only when the officer or agent owes an independent duty of reasonable care to the injured party apart from the employer's duty.”) (quoting *Leitch v. Hornsby*, 935 S.W.2d 114, 117 (Tex. 1996)). Consequently, there is no reasonable possibility Plaintiffs could recover against the detailers under these theories in state court.

b. Even assuming the detailers could be considered “non-manufacturing sellers,” the evidence establishes they are not liable to Plaintiffs.

Even assuming *arguendo* that the detailers could be deemed “non-manufacturing sellers” under Texas law (and they cannot for the reasons stated above), as of 2003, Texas eliminated liability for “downstream” sellers who sold a product alleged to be defectively designed or manufactured by another except in very limited circumstances, none of which are applicable here. Section 82.003(a) of the Texas Civil Practice and Remedies Code, as amended, now states:

- (a) A seller that did not manufacture a product is not liable for harm caused to the claimant by that product unless the claimant proves:
 - (1) that the seller participated in the design of the product;
 - (2) that the seller altered or modified the product and the claimant's harm resulted from the alteration or modification;
 - (3) that the seller installed the product, or had the product installed on another product and the claimant's harm resulted from the product's installation onto the assembled product;
 - (4) that:
 - (A) the seller exercised substantial control over the content of a warning or instruction that accompanied the product;
 - (B) the warning or instruction was inadequate; and
 - (C) the claimant's harm resulted from the inadequacy of the warning or instruction;
 - (5) that:
 - (A) the seller made an express factual representation about an aspect of the product;
 - (B) the representation was incorrect;
 - (C) the claimant relied on the representation in obtaining or using the product; and

- (D) if the aspect of the product had been as represented, the claimant would not have been harmed by the product or would not have suffered the same degree of harm;
- (6) that:
 - (A) the seller actually knew of a defect to the product at the time the seller supplied the product; and
 - (B) the claimant's harm resulted from the defect; or
- (7) that the manufacturer of the product is:
 - (A) insolvent; or
 - (B) not subject to the jurisdiction of the court.

TEX. CIV. PRAC. & REM. CODE ANN. § 82.003 (Vernon 2005). Plaintiffs do not allege that the detailers could be held liable under subsections (2), (3), or (7) of the statute. Further, Pfizer's evidence establishes that none of the other four possible exceptions – subsections (1), (4), (5), and (6) – apply here. The detailers had no involvement in the design of Bextra® (as required by (1)); no control over content of the package inserts or other written warnings (as required by (4)); made no representations about Bextra® to Plaintiffs (as required by (5)); and had no knowledge that the product was defective and did not “supply” the product to Plaintiff (as required by (6)). See GUERRERO DECL. at ¶¶ 5, 7-10 (Exhibit 6A); DAVIS DECL. at ¶¶ 5, 7-10 (Exhibit 6B); JALUFKA DECL. at ¶¶ 6, 8-11 (Exhibit 6C); NELSON DECL. at ¶¶ 6, 8-11 (Exhibit 6D); HAHN DECL. at ¶¶ 6, 8-11 (Exhibit 6E); VIAL DECL. at ¶¶ 6, 8-11 (Exhibit 6F); TRUITT DECL. at ¶¶ 6, 8-11 (Exhibit 6G); MCLUHAN DECL. at ¶¶ 7, 9-12 (Exhibit 6H); RIOJAS DECL. at ¶¶ 6, 8-11 (Exhibit 6I); MEZA DECL. at ¶¶ 5-7 (Exhibit 6J); BARINEAU DECL. at ¶¶ 5, 7-10 (Exhibit 6K); ZEPLIN DECL. at ¶¶ 5, 7-10 (Exhibit 6L); QUINONES DECL. at ¶¶ 5, 7-10 (Exhibit 6M); GOODSON DECL. at ¶¶ 5, 7-10 (Exhibit 6N); RODRIGUEZ DECL. at ¶¶ 5, 7-10 (Exhibit 6O); SILVA DECL. at ¶¶ 5, 7-10 (Exhibit 6P); PONCE DECL. at ¶¶ 5, 7-10 (Exhibit 6Q); ESCOBAR DECL. at ¶¶ 5, 7-10 (Exhibit 6R); GUIDRY DECL. at ¶¶ 7, 9-12 (Exhibit 6S); TOWNSEND DECL. at ¶¶ 5, 7-10 (Exhibit 6T); ADAME DECL. at ¶¶ 5, 7-10 (Exhibit 6U). Thus, again, there is no reasonable possibility Plaintiffs could establish a claim against them in state court. See, e.g., *Garcia v. Nissan Mtr. Co., Ltd.*, No. M-05-59, 2006 WL 869944, *4 (S.D. Tex. Mar. 30, 2006) (holding that

undisputed declaration from non-diverse defendant establishing it lacked knowledge of defect that potentially could make it liable under § 83.002(a)(6) demonstrated improper joinder).

2. *Plaintiffs' failure-to-warn and misrepresentation-type claims also do not state cognizable claims against the detailers under Texas law.*

Although vaguely drafted, the gist of Plaintiffs' complaint against the detailers appears to be that they passed along – and did not correct – allegedly incorrect information provided by Pfizer regarding the safety and risk profile of Bextra® to health care providers. *See, e.g.,* PETITION 7 (stating that detailer defendants “called on doctors and hospitals” regarding Bextra® and “were in a position to make representations about the risks” associated with use of that drug). These allegations fail to state viable claims under Texas law because they are based on the mistaken premise that the Pfizer representatives *individually* owed physicians (and patients) a duty to warn about risks of taking Bextra®. It is Pfizer – the seller of Bextra® – that owed a duty to warn prescribing physicians of known or foreseeable side effects associated with that drug.⁸ Pfizer contends that it fulfilled this duty, but even if it did not, the detailer employees are not personally liable for Pfizer's failure to warn. Employees do not assume individual, personal liability in the absence of an independent duty merely by participating in their employer's alleged failure to provide adequate information about its products. “[I]ndividual liability arises only when the officer or agent owes an independent duty of reasonable care to the injured party apart from the employer's duty,” *Tri v. J.T.T.*, 162 S.W.3d 552, 562 (Tex. 2005) (quoting *Leitch v. Hornsby*, 935 S.W.2d 114, 117 (Tex. 1996)), or when the agent knowingly participates in

⁸ The learned intermediary doctrine establishes that Pfizer's duty is to communicate appropriate warnings to the prescribing physician; Pfizer had no duty to warn patients directly. *See, e.g., Wyeth-Ayerst Labs. Co. v. Medrano*, 28 S.W.3d 87, 91 (Tex. App. – Texarkana 2000, no pet.). Although Pfizer contends the detailer defendants owed no duty to warn, even if they did owe such a duty, the learned intermediary doctrine would apply to them as well. *See In re Rezulin Prods. Liab. Litig.*, 133 F. Supp. 2d 272, 288-90 (S.D.N.Y. 2001) (extending learned intermediary doctrine to detailers under Mississippi law); *Johnson v. Parke-Davis*, 114 F. Supp. 2d 522, 524-25 (S.D. Miss. 2000) (same).

fraudulent or tortious conduct. *See Kingston v. Helm*, 82 S.W.3d 755, 759 (Tex. App.—Corpus Christi 2002, pet. denied).

The duty to warn is owed by the product's "seller." *Jaimes v. Fiesta Mart, Inc.*, 21 S.W.3d 301, 305 (Tex. App. – Houston [1st Dist.] 1999, pet. denied). As discussed above, however, the detailers are not "sellers" of Bextra® under Texas law, and owe no independent duty to warn apart from that owed by their employer. *In re Diet Drugs Prods. Liab. Litig.*, No. 03-20546, 2004 WL 1535828, *10 (E.D. Pa. July 6, 2004) ("While the product's 'seller' owes the consumer a duty to warn of a product's dangers, [the pharmaceutical manufacturer], and not the sales representatives, was the 'seller.' . . . Accordingly, the sales representatives owed no independent duty to warn under Texas law."); *see also, e.g., In re Diet Drugs Prods. Liab. Litig.*, 220 F. Supp. 2d 414, 425 (E.D. Pa. 2002) ("[S]ales representatives are not considered 'sellers' under Mississippi law, but rather, employees of the businesses who are sellers.").

Indeed, pharmaceutical detailers cannot possibly owe an individual duty to warn. They have no control over the content of the FDA-approved (and FDA-mandated) package insert or other written warnings supplied to health care providers by Pfizer. *See, e.g., DAVIS DECL.* at ¶ 5 (Exhibit 6B). Even assuming, *arguendo*, that a detailer could be responsible for giving oral warnings, this would require unfettered, personal access to physicians, which detailers lack – some physicians refuse to meet with detailers at all; others meet with them for less than ten minutes. *Id.* at ¶ 3. Imposing on detailers an individual duty to warn would require them to spend their brief visits – assuming they even got one – reiterating every known side effect contained in the product's FDA-approved labeling in order to avoid practically unlimited personal liability. Moreover, it makes no sense to make a non-physician detailer personally liable for failing to give oral warnings to a medically-trained professional about a prescription

drug that is exhaustively described in FDA-approved prescribing information in an FDA-approved format. For the reasons discussed above, Texas law does not require this absurd result.

Numerous Texas federal courts have held that prescription drug users have no reasonable possibility of establishing the personal liability of individual detailers based on these theories and have found that they are improperly joined in an action against their employer, the manufacturer. Even prior to the creation of MDL-1699, the late Judge Howell Cobb issued four different orders in the Celebrex®/Bextra® litigation finding improper joinder in cases removed to the Eastern District of Texas based on virtually identical allegations. *See Hebert v. Pfizer Inc.*, No. 1:05-CV-418-HC, slip op. at 1-2 (E.D. Tex. Aug. 18, 2005) (Exhibit 7A); *Pickens v. Pfizer Inc.*, No. 1:05-CV-528-HC, slip op. at 1-2 (E.D. Tex. Aug. 18, 2005) (Exhibit 7B); *Knight v. Pfizer Inc.*, No. 1:05-CV-529-HC, slip op. at 1-2 (E.D. Tex. Aug. 17, 2005) (Exhibit 7C); *Boudreaux v. Pfizer Inc.*, No. 1:05-CV-369-HC, slip op. at 1-2 (E.D. Tex. July 17, 2005) (Exhibit 7D).

Other Texas federal courts – including this Court – also have found that no viable claim existed against individual detailers when faced with substantially similar issues of improper joinder. *See, e.g., Budd v. Wyeth*, Case No. A-03-CA-465-SS, slip op. at 6 (W.D. Tex. Sept. 17, 2003) (Sparks, J.) (“[B]ecause the detailers do not have duty to research and ensure the safety [sic] fen-phen separate from Wyeth’s duty, [plaintiff] does not have a reasonable possibility of success on her misrepresentation claims against the detailers under Texas law.”) (Exhibit 7E); *Lewis v. Wyeth*, No. 1:03-CV-166-C, slip op. at 7 (N.D. Tex. Feb. 17, 2004) (Cummings, J.) (concluding that, under Texas law, plaintiff had “no reasonable possibility of success on any claims for negligence on the part of [Wyeth’s] sales representatives.”) (Exhibit 7F); *Northcutt v. Wyeth*, No. H-03-2665, slip op. at 5 (S.D. Tex. Aug. 13, 2003) (Rosenthal, J.) (“There is no allegation nor presentation of any facts that would create an independent duty owing from these individual employees to Northcutt, apart from the duty owing by Wyeth, that was violated.”)

(Exhibit 7G); *Nightingale v. Wyeth*, No. W-03-CA-203 (W.D. Tex. Sept. 5, 2003) (Smith, Jr., J.) (“Plaintiffs have identified no duty under Texas law which either Defendant owed to Plaintiffs or violated.”) (Exhibit 7H); *Ferguson v. Wyeth*, No. 4:03-CV-5141 (S.D. Tex. Jan. 30, 2004) (Hoyt, J.) (“The Court is of the opinion that these sales representatives cannot warrant or make representations about pharmaceutical products that would override the disclosure that is required of and made by the manufacturer of the drugs.”) (Exhibit 7I). The detailer employees named in this case likewise are improperly joined.

Any negligent misrepresentation claim fails for an additional reason. To recover for negligent misrepresentation, a plaintiff actually must have received and relied upon the alleged misrepresentation. *Harco Energy, Inc. v. Re-Entry People, Inc.*, 23 S.W.3d 389, 396 (Tex. App. – Amarillo 2000, no pet.). The detailers’ declarations confirm they did not make any representations regarding Bextra® directly to Plaintiffs.⁹ Nor do Plaintiffs’ allege they make any representations to the prescribing doctor that the doctor passed along to Plaintiffs. But Plaintiffs could not recover from the detailers as an “indirect recipient” of a misrepresentation in any event. Texas has adopted Section 552 of the Restatement (Second) of Torts, which limits liability for negligent misrepresentation to “the person or one of a limited group of persons for whose benefit and guidance [the defendant] intends to supply the information or knows that the recipient intends to supply it[.]” RESTATEMENT (SECOND) OF TORTS § 552(2)(a) (1977); *Fed. Land Bank Ass’n of Tyler v. Sloane*, 825 S.W.2d 439, 442 (Tex. 1991) (adopting Section 552). As interpreted by Texas courts, “the Restatement requires actual knowledge of the recipient’s

⁹ See GUERRERO DECL. at ¶ 8 (Exhibit 6A); DAVIS DECL. at ¶ 8 (Exhibit 6B); JALUFKA DECL. at ¶ 9 (Exhibit 6C); NELSON DECL. at ¶ 9 (Exhibit 6D); HAHN DECL. at ¶ 9 (Exhibit 6E); VIAL DECL. at ¶ 9 (Exhibit 6F); TRUITT DECL. at ¶ 9 (Exhibit 6G); MCLUHAN DECL. at ¶ 10 (Exhibit 6H); RIOJAS DECL. at ¶ 9 (Exhibit 6I); MEZA DECL. at ¶ 7 (Exhibit 6J); BARINEAU DECL. at ¶ 8 (Exhibit 6K); ZEPLIN DECL. at ¶ 8 (Exhibit 6L); QUINONES DECL. at ¶ 8 (Exhibit 6M); GOODSON DECL. at ¶ 8 (Exhibit 6N); RODRIGUEZ DECL. at ¶ 8 (Exhibit 6O); SILVA DECL. at ¶ 8 (Exhibit 6P); PONCE DECL. at ¶ 8 (Exhibit 6Q); ESCOBAR DECL. at ¶ 8 (Exhibit 6R); GUIDRY DECL. at ¶ 10 (Exhibit 6S); TOWNSEND DECL. at ¶ 8 (Exhibit 6T); ADAME DECL. at ¶ 8 (Exhibit 6U).

identity and a specific intent on the part of the alleged tortfeasor that the claimant would rely on the misrepresentation.” *Trans-Gulf Corp. v. Performance Aircraft Servs., Inc.*, 82 S.W.3d 691, 696 (Tex. App.–Eastland 2002, no pet.). Even a claim for fraud requires that the defendant intend that the plaintiff receive and rely upon the allegedly false communication. *Great Plains Trust Co.*, 313 F.3d at 322. Plaintiffs have not alleged (and cannot seriously contend) that the detailers were aware of their specific identities, much less that they made representations to Harold Walker’s physician with the specific intent that they be repeated to, and relied upon, by him.

3. Any allegation of “knowing” misrepresentation or fraud against the local defendants also is rebutted by the detailers’ sworn declarations.

The detailers also are improperly joined because any allegation of “knowing” misconduct – and there is none – is rebutted by Pfizer’s proof. The detailers’ sworn declarations are clear that they “never intentionally misrepresented the safety, efficacy, or risk profile of Bextra® to any health care provider or patient” and “never knowingly made a false or misleading statement about Bextra® to any health care provider or Bextra® user.”¹⁰ See GUERRERO DECL. at ¶ 12 (Exhibit 6A); DAVIS DECL. at ¶ 12 (Exhibit 6B); JALUFKA DECL. at ¶ 13 (Exhibit 6C); NELSON DECL. at ¶ 13 (Exhibit 6D); HAHN DECL. at ¶ 13 (Exhibit 6E); VIAL DECL. at ¶ 13 (Exhibit 6F); TRUITT DECL. at ¶ 13 (Exhibit 6G); MCLUHAN DECL. at ¶ 14 (Exhibit 6H); RIOJAS DECL. at ¶ 13 (Exhibit 6I); BARINEAU DECL. at ¶ 12 (Exhibit 6K); ZEPLIN DECL. at ¶ 11 (Exhibit 6L); QUINONES DECL. at ¶ 12 (Exhibit 6M); GOODSON DECL. at ¶ 11 (Exhibit 6N); RODRIGUEZ DECL. at ¶ 12 (Exhibit 6O); SILVA DECL. at ¶ 12 (Exhibit 6P); PONCE DECL. at ¶ 12 (Exhibit 6Q); ESCOBAR DECL. at ¶ 12 (Exhibit 6R); GUIDRY DECL. at ¶ 14 (Exhibit 6S); TOWNSEND DECL. at ¶ 12 (Exhibit 6T); ADAME DECL. at ¶ 12 (Exhibit 6U). Indeed, all of the information and material

¹⁰ Two of the detailers named by Plaintiffs never marketed, distributed, sold, or promoted Bextra®. See MEZA DECL. ¶ 5 (Exhibit 6J); BARINEAU DECL. ¶ 3 (Exhibit 6K). Those defendants never called on a single physician or health care provider regarding that drug. *Id.*

the representatives used to detail Pfizer's drugs was derived exclusively from the education provided to them by Pfizer. *See, e.g.,* DAVIS DECL. at ¶ 5.¹¹ They did not, as field representatives, conduct independent research regarding the drugs they detailed. *Id.* at ¶ 6. They have no knowledge that any of the information provided to them by Pfizer about Bextra® is incorrect. *Id.* at ¶ 9.

The detailers' declarations negate any allegation that they knowingly participated in any tortious conduct. When presented with similar proof, Texas federal courts – including this Court – have held that it established that the individual pharmaceutical detailers were improperly joined. *See, e.g., Kollman v. Wyeth*, No. A-04-CA-034-SS, slip op. at (W.D. Tex. Mar. 15, 2004) (holding non-diverse detailer defendant fraudulently joined where removing defendant had negated the facts that might form the basis for a state law claim against the detailer) (Exhibit 7J); *Lewis v. Wyeth*, No. 1:03-CV-166-C, slip op. at 7-8 (N.D. Tex. Feb. 17, 2004) (holding that plaintiff's fraud and misrepresentation claims were rebutted by declarations from non-diverse sales representatives and that those defendants were fraudulently joined) (Exhibit 7F); *Nightingale v. Wyeth, Inc.*, No. W-03-CA-203, slip op. at 3 (W.D. Tex. Sept. 5, 2003) (holding non-diverse detailer defendants fraudulently joined where plaintiffs had not presented anything to refute those defendants' sworn testimony that no misrepresentations were made regarding the uses of the drugs in question) (Exhibit 7H). Other federal courts have agreed. *See, e.g., Legg v. Wyeth*, 428 F.3d 1317, 1323-24 (11th Cir. 2005) (concluding that there was no reasonable possibility of recovery against nondiverse detailer where detailer had submitted sworn statement refuting plaintiff's claims and plaintiff had not provided any contrary evidence); *McCluskey v. Merck & Co., Inc.*, No. 07-AR-0232-S, slip op. at 11-13 (N.D. Ala. Mar. 7, 2007) (holding allegations of fraud and fraudulent misrepresentation rebutted by Pfizer detailers' uncontested

¹¹ Each of the detailers have attested to these same facts in their respective declarations.

declarations) (Exhibit 7K); *Gordon*, 2006 WL 2337002, at *7 (same); *In re Diet Drugs Prods. Liab. Litig.*, No. 03-20765, 2004 WL 1824357, *4 (E.D. Pa. Aug. 12, 2004) (holding that allegations of knowing participation in fraudulent or tortious conduct were rebutted by non-diverse detailer defendants' sworn testimony); *Sobkowski v. Wyeth*, No. 5:04-CV-96-Oc-10GRD (M.D. Fla. May 17, 2004) (magistrate's report and recommendation), *adopted by Sobkowski v. Wyeth*, No. 5:04-CV-96-Oc-10GRJ (M.D. Fla. June 24, 2004) (holding that plaintiff's fraud claim against non-diverse sales representatives did not defeat removal where allegations of fraud were rebutted by uncontested affidavits of sales representatives) (Exhibit 7L).

IV.

Amount in Controversy

The amount-in-controversy requirement of 28 U.S.C. § 1332(a) is plainly satisfied. Plaintiffs allege that, as a result of ingesting Bextra®, Harold Walker sustained serious and permanent injuries. PETITION at 1. They are seeking unlimited compensatory damages for, *inter alia*, physical pain and mental anguish, medical expenses, and loss of consortium. *Id.* at 12. They also seek unlimited punitive damages for Pfizer's alleged "gross negligence." *Id.* at 11. It is facially apparent from the petition that Plaintiffs seek recovery of an amount in excess of \$75,000, exclusive of interest and costs. *See, e.g., De Aguilar v. Boeing Co.*, 11 F.3d 55, 57 (5th Cir. 1993) (stating that where it is "facially apparent" from the state-court petition that the amount in controversy exceeds the jurisdictional minimum, then the defendant need only point such fact out to successfully bear its burden); *see also Lockett v. Delta Airlines, Inc.*, 171 F.3d 295, 298 (5th Cir. 1999) (concluding that district court did not err in finding that personal injury claims exceeded \$75,000 where the claimant alleged "damages for property, travel expenses, an emergency ambulance trip, a six day stay in the hospital, pain and suffering, humiliation, and her temporary inability to do housework after the hospitalization."); *Morrow v. Wyeth*, No. B-05-

209, 2005 WL 2621555, *3 (S.D. Tex. Oct. 13, 2005) (unpublished) (concluding that amount-in-controversy was satisfied in pharmaceutical product liability case where plaintiff alleged “severe injuries,” including “serious injuries to his central nervous system”); *Matney v. Wenger Corp.*, 957 F. Supp. 942, 943 (S.D. Tex. 1997) (holding that a products liability complaint asserting claims for personal injury, past and future medical expenses, mental anguish, and exemplary damages met the amount-in-controversy threshold).

V.

Consent to Removal

The detailer defendants are improperly joined in an attempt to defeat diversity and prevent removal. Consequently, their consent is not required for removal. *See Jernigan v. Ashland Oil Inc.*, 989 F.2d 812, 815 (5th Cir. 1993); *Farias v. Bexar Co. Bd. of Trustees*, 925 F.2d 866, 871 (5th Cir. 1991). In any event, those detailers who have been served at the time of removal (Defendants Jalufka, Vial, Zeplin, Goodson, and Adame) consent to removal of this cause to this Court. *See Nixon v. Wheatley*, 368 F. Supp. 2d 635, 639 (E.D. Tex. 2005) (holding that statement in notice of removal that defendants, who were represented by the same counsel, joined the removal was sufficient to satisfy unanimity requirement). The consent of the unserved detailer defendants is not required. *Getty Oil Corp. v. Ins. Co. of North Am.*, 841 F.2d 1254, 1262 n.9 (5th Cir. 1988).

VI.

Removal is Timely

Pfizer is the only properly joined defendant in this case, and all other defendants, as discussed above, are improperly joined. Pfizer was first served with citation on May 7, 2007, less than 30 days before its Notice of Removal is being filed. Accordingly, this removal is

timely. *See* 28 U.S.C. § 1446(b); *Murphy Bros., Inc. v. Michetti Pipe Stringing, Inc.*, 526 U.S. 344, 347–48 (1999).

VII.

Proper Court for Removal

The United States District Court for the Western District of Texas, Austin Division, embraces Caldwell County, the county in which the state court action is now pending. *See* 28 U.S.C. § 124(d)(1). Thus, this case is properly removed to this Court pursuant to 28 U.S.C. § 1441(a).


VIII.

Conclusion

Upon filing of this Notice of the removal of this cause, written notice of the filing is being given by Defendant to Plaintiffs and counsel, and is being filed with the Clerk of the state court in which this cause was originally filed, as required by 28 U.S.C. § 1446(d). A copy of those notices with proof of service of them is attached hereto as Exhibits 2J and 2K.

WHEREFORE, Defendant Pfizer hereby removes the above-styled action pending against it in the 421st Judicial District Court of Caldwell County, Texas, to this Honorable Court.

Respectfully submitted,



Kenneth J. Ferguson

Attorney-in-charge

State Bar No. 06918100

E-mail: kjf@ctw.com

Leslie A. Benitez

State Bar No. 02134300

E-mail: lab@ctw.com

Kelly R. Kimbrough

State Bar No. 00794984

E-mail: krk@ctw.com

J. Andrew Hutton

State Bar No. 24012878

E-mail: ahl@ctw.com

CLARK, THOMAS & WINTERS

A PROFESSIONAL CORPORATION

P.O. Box 1148

Austin, Texas 78767

(512) 472-8800

(512) 474-1129 [Fax]

**ATTORNEYS FOR DEFENDANTS
PFIZER INC.**

CERTIFICATE OF SERVICE

I hereby certify that the foregoing document was forwarded in the manner described below to the following interested parties on June 1, 2007.

Via Certified Mail/Return Receipt Requested

Kathryn Snapka

Greg W. Turman

Richard B. Waterhouse, Jr.

Aditi Anita Shahani

SNAPKA, TURMAN & WATERHOUSE, L.L.P.

606 N. Carancahua, Suite 1511

Corpus Christi, Texas 78476

Attorneys for Plaintiffs

